ライフサイエンスコーパス: catestatin

1 sible mechanistic explanation for diminished catestatin.

2 diminished CHGA secretion and processing to catestatin.

3 he catecholamine release-inhibitory fragment catestatin.

4 polymorphisms in the amino acid sequence of catestatin.

5 nist chlorisondamine or the novel antagonist catestatin.

6 CgA that are utilized in the biosynthesis of catestatin.

7 ynthesis of chromogranin A, the precursor of catestatin.

8 ubstantially blocked in the adrenal gland by catestatin.

9 ry, nicotinic cholinergic antagonist peptide catestatin.

10 l transduction was specifically disrupted by catestatin.

11 esting diminished conversion of precursor to catestatin.

12 human Chga and exogenous injection of human catestatin, a CHGA-derived nicotinic cholinergic antagon

13 A model for catestatin action in the baroreceptor center of the nucl

14 And does catestatin antagonize secretion and transcription in viv

15 Human, bovine, and rat catestatins (as well as substance P) had similar potenci

16 -dependent fashion, the nicotinic antagonist catestatin blocked agonist desensitization of both catec

17 cells was accompanied by the cosecretion of catestatin (CgA(344)(-)(364)) and variant peptide forms

18 A catecholamine release-inhibitory fragment, catestatin (chromogranin A344-364), on agonist-induced d

19 loci on chromosomes 4q35 and 5q34 affecting catestatin concentration (P = 3.40 x 10-30 for rs4253311

20 influenced CHGA secretion and processing to catestatin, confirming the mechanism of a novel trans-QT

21 Catestatin-containing polypeptides, demonstrated by anti

22 rocessing in HF and whether the CgA fragment catestatin (CST) may directly influence cardiomyocyte fu

23 e were treated with the CHGA-derived peptide catestatin (CST) that is deficient in these mice.

24 Catestatin (CST), a chromogranin A (CHGA)-derived peptid

25 In this study, we investigated whether catestatin (Cst), a peptide derived from the neuroendocr

26 desensitization by nicotinic agonists, since catestatin did not block desensitization of catecholamin

27 horter (chromogranin A(344-364)) versions of catestatin each inhibited catecholamine release from chr

28 es near unity suggested noncooperativity for catestatin effects on both nicotinic responses (secretor

29 On mass spectrometry, a major catestatin form was bovine chromogranin A(332-364); iden

30 lamine secretory granule biogenesis, and its catestatin fragment inhibits catecholamine release.

31 Thus, chromogranin A and its catestatin fragment may lie at the nexus of nicotinic ch

32 The catestatin fragment of chromogranin A is an endogenous i

33 The catestatin fragment of chromogranin A is an inhibitor of

34 Knowledge of cleavage sites of catestatin from chromogranin A may provide a useful star

35 The catestatin Gly364Ser variant causes profound changes in

36 dentified a natural nonsynonymous variant of catestatin, Gly364Ser, that alters human autonomic funct

37 We approached catestatin heritability using twin pairs, coupled with g

38 Loss of the physiological "brake" catestatin in Chga mice coupled with dysregulation of tr

39 Here we found extensive processing of catestatin in chromogranin A, as judged by catestatin ra

40 We established heritability of catestatin in twins from 2 continents.

41 Heritability for catestatin in twins was 44% to 60%.

42 an CHGA haplotype in order to probe CHGA and catestatin in vivo.

43 is, necessary for catecholamine storage, and catestatin-induced inhibition of cholinergic-stimulated

44 the primary sequences of high molecular mass catestatin intermediates and peptides to define the prot

45 Secretion of catestatin intermediates from chromaffin cells was accom

46 icted that production of high molecular mass catestatin intermediates requires cleavage at the COOH-t

47 emonstrated the presence of 54-56 and 50 kDa catestatin intermediates that contain the NH(2) terminus

48 The COOH termini of these catestatin intermediates were defined by the presence of

49 hese findings demonstrate that production of catestatin involves cleavage of CgA at paired basic and

50 We conclude that catestatin is a highly potent, dose-dependent, noncompet

51 Catestatin is an active 21-residue peptide derived from

52 In chromaffin granules, the major form of catestatin is cleaved at dibasic sites, while smaller ca

53 We conclude that catestatin is cleaved extensively in vivo, and the pepti

54 ts catecholamine release-inhibitory fragment catestatin is diminished, and low catestatin predicts au

55 from the chromogranin A (CgA) precursor, and catestatin is secreted from neuroendocrine chromaffin ce

56 However, it is notable that production of catestatin itself (CgA(344)(-)(364)) utilizes more unusu

57 Catestatin itself blocks stimulation of both secretion a

58 Linkage identified 3 regions contributing to catestatin, likely novel determinants of sympathochromaf

59 umans suggest a mechanism whereby diminished catestatin might increase the risk for hypertension.

60 and monobasic residues, necessary steps for catestatin peptide regulation of nicotinic cholinergic-i

61 HGA-derived catecholamine release-inhibitory catestatin peptides.

62 y incompletely blocked by chlorisondamine or catestatin, perhaps because of limited blood-brain barri

63 y fragment catestatin is diminished, and low catestatin predicts augmented adrenergic pressor respons

64 roduction, chromogranin A precursor, and its catestatin product.

65 f catestatin in chromogranin A, as judged by catestatin radioimmunoassay of size-fractionated chromaf

66 Natural allelic variation in the catestatin region was predicted to disrupt the coiled-co

67 Radioimmunoassay demonstrated catestatin release from the regulated secretory pathway

68 to normalcy was achieved by either exogenous catestatin replacement or humanization of Chga mice.

69 eceptor alpha/beta subunits and that crucial catestatin residues are likely to be identical across th

70 Peptide nicotinic antagonists (catestatins, substance P) were far more potent inhibitor

71 had elevated CHGA coupled with reduction in catestatin, suggesting diminished conversion of precurso

72 d a genome-wide association study for plasma catestatin, the catecholamine release inhibitory peptide

73 When catestatin variants were mixed in likely heterozygotic (

74 kallikrein cleaved recombinant human CHGA to catestatin, verified by mass spectrometry.

75 Human catestatin was cleaved in pheochromocytoma chromaffin gr

76 ogranin A344-364 [RSMRLSFRARGYGFRGPGLQL], or catestatin) was a potent, dose-dependent (IC50 approxima

77 etermines CHGA trafficking and processing to catestatin, we genotyped at positional candidate ATP6N1,

78 Circulating levels of catestatin were lower among those with hypertensive ESRD

79 ontaining polypeptides, demonstrated by anti-catestatin western blots, of 54-56, 50, 32, and 17 kDa c

80 ogically active peptide fragments, including catestatin, which inhibits catecholamine release.